CLARAVA

Welcome to the Brand page for “CLARAVA”, which is offered here for Medical diagnostic blood or biopsy testing reagents and assays for advanced next-generation sequencing science for creating immune profiling of kidney transplant recipients for predicting and identifying risk of graft rejection; medical diagnostic reagents consisting primarily of reagents for use in disease testing and prediction; nucleic acid sequences and chemical reagents for medical purposes;medical profile and medical record analysis designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms; medical analysis services for predicting and identifying risk of graft rejection in kidney transplant patients; none of the foregoing in the fields of business analytics, market intelligence, or business intelligence;blood test collection kit comprised of blood collection tube and bag, and holder for medical sample tubes, for predicting and identifying the risk of graft injury and graft loss in kidney transplant recipients;development of new technology for others in the field of medical devices and medical diagnostic apparatuses; research, development and consultation related thereto in the field of medical devices and medical diagnostic apparatuses through the use of artificial intelligence; laboratory research in the field of kidney transplant; medical research services; computer software development; providing temporary use of on-line non-downloadable software and software applications using artificial intelligence for medical analysis; none of the foregoing in the fields of business analytics, market intelligence, or business intelligence;.

Its status is currently believed to be active. Its class is unavailable. “CLARAVA” is believed to be currently owned by “Verici Dx Plc”.